Kevin D. Cordell, formerly vice president of sales for the GI Solutions business at Covidien Ltd, has been appointed president of U.S. Extremities at Wright Medical Group, Inc. Cordell is managing Wright’s U.S. extremities and biologic business and reports directly to the chief operating officer.
Pascal Girin, Wright’s executive vice president and chief operating officer stated in the September 15, 2014 news release, “For over 20 years, Kevin has led the development, implementation and execution of successful commercial strategies and programs for global medical device, biotech and pharmaceutical companies. His proven track record of success and his passion for building high performing commercial organizations will serve us well as we continue to focus on accelerating revenue growth, driving sales rep productivity gains in our U.S. foot and ankle business, and launching new products, in particular our new INFINITY ankle.”
The news release indicates that while at Covidien, Cordell also served in the capacity of vice president of sales & global marketing for its Peripheral Vascular business. “He joined Covidien in July 2010 through the acquisition of ev3 Inc., where he served as vice president of U.S. sales from January 2009 to July 2010. Prior to ev3, Mr. Cordell served as vice president, global sales of FoxHollow Technologies, Inc. from March 2007 to October 2007. Earlier in his career, Mr. Cordell also held various positions of increasing responsibility for Johnson & Johnson’s Cordis Cardiology and Centocor companies. He received his bachelor’s degree in finance from the University of Oklahoma.”
Robert Palmisano, Wright’s president & chief executive officer commented, “Kevin is an accomplished senior executive with a demonstrated history of leading direct sales organizations and developing fast-growing, underpenetrated markets, and I’m delighted to welcome him to the Wright management team. His deep experience and strong capabilities will be instrumental as we continue to drive our success in our U.S. extremities and biologics markets.”
Cordell told OTW, “I’m delighted to join the Wright Medical team and support the continued growth of the U.S. Extremities business. My top near-term priorities will be to continue our focus on accelerating revenue growth, launching new products, including the new INFINITY total ankle system, and driving sales productivity gains in our U.S. foot and ankle sales organization. I am also looking forward to working with the rest of the Wright leadership team as we work to further extend our leadership position in Extremities and Biologics.”
